Kingstone Capital Partners Texas LLC Makes New $40.74 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Kingstone Capital Partners Texas LLC acquired 77,592 shares of Regeneron Pharmaceuticals, valued at approximately $40.7 million, during the second quarter.
• Regeneron Pharmaceuticals reported $12.89 EPS for the last quarter, exceeding estimates by $4.46, with a revenue of $3.68 billion, significantly above forecasts.
• The company recently declared a quarterly $0.88 dividend, with a total annualized payout of $3.52, indicating a dividend yield of 0.6%.

Kingstone Capital Partners Texas LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 77,592 shares of the biopharmaceutical company's stock, valued at approximately $40,736,000. Kingstone Capital Partners Texas LLC owned 0.07% of Regeneron Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Brighton Jones LLC boosted its holdings in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after acquiring an additional 686 shares during the last quarter. American Assets Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $427,000. Waverly Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 23.0% in the fourth quarter. Waverly Advisors LLC now owns 1,280 shares of the biopharmaceutical company's stock valued at $912,000 after acquiring an additional 239 shares during the last quarter. CSS LLC IL acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $435,000. Finally, Vise Technologies Inc. boosted its holdings in Regeneron Pharmaceuticals by 69.8% in the fourth quarter. Vise Technologies Inc. now owns 786 shares of the biopharmaceutical company's stock valued at $560,000 after acquiring an additional 323 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on REGN. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price target on the stock. BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. Finally, Jefferies Financial Group upped their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research note on Wednesday, August 27th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $6.72 on Friday, reaching $591.99. The stock had a trading volume of 2,177,965 shares, compared to its average volume of 914,839. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,154.56. The firm has a market capitalization of $62.74 billion, a price-to-earnings ratio of 14.92, a P/E/G ratio of 1.98 and a beta of 0.35. The firm's 50-day moving average is $567.77 and its two-hundred day moving average is $575.13. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the business earned $11.56 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.